Important Research
Robbie Majzner, MD, is Director of the Pediatric and Young Adult Cancer Cell Therapy Program at Dana-Farber Cancer Institute/Boston Children’s Hospital. He is focused on the development and deployment of immunotherapies for pediatric cancer. He received his MD from Harvard Medical School, followed by training in Pediatrics at New York Presbyterian-Columbia and Pediatric Hematology-Oncology at Johns Hopkins and the National Cancer Institute. His work in the laboratory centers on engineering platform technologies to improve the efficacy of CAR T cells in solid tumors and overcome therapeutic resistance. Concurrently, he is focused on translating laboratory advances in innovative immunotherapy clinical trials for children and adults with incurable cancers.
SCROLL DOWN FOR RECENT ARTICLES THAT MAY INTEREST YOU
Articles You May Be Interested In…
-
Scientists create ‘immune-activating’ molecule to help the body fight cancer
Researchers at Weizmann Institute of Science have developed a new immune-activating molecule that targets macrophages in tumors—transforming them from cancer-helping to cancer-fighting. This molecule, tested in preclinical models of lung and kidney cancer, caused significant tumor shrinkage by activating both NK cells and T cells. The approach offers a promising new path—especially for cancers that don’t respond well to existing immunotherapies.
-
Israeli team develops new treatment that helps immune system fight tumors more effectively
New treatment targets specialized immune‑suppressing macrophages in tumor microenvironment; these macrophages express a receptor called TREM2 and have been shown to contribute to poor responses to therapy and decreased survival in cancer patients
-
'Troubling Side Effects Due To Lack of Funding'
The article, by Meghan Holohan, discusses the urgent need for increased funding for childhood cancer treatments, highlighting the disparities in research and support compared to adult cancers. It discusses efforts and initiatives aimed at improving treatment options and outcomes for young patients facing rare and aggressive forms of cancer.
-
NCI Research Portfolio: Driving Discovery to End Cancer as We Know It
This article highlights the National Cancer Institute's diverse research portfolio, showcasing advancements in cancer treatment, prevention, and early detection. It outlines key projects and initiatives aimed at improving outcomes for cancer patients.
-
News in Cell and Gene Therapy for Rare Cancer Day 2024
This article discusses the significance of Rare Cancer Day 2024 and highlights advancements in cell therapy for treating rare cancers. It emphasizes the importance of raising awareness and fostering research to improve outcomes for patients with these less common diseases. goes here
-
'Australian children with neuroblastoma given free access to $500,000 cancer drug DFMO'
By political reporters Jake Evans and Evelyn Manfield
This article reports on a breakthrough regarding the availability of the cancer drug DFMO for children with neuroblastoma, a rare and aggressive cancer. It highlights the efforts to ensure free access to this treatment, aiming to improve survival rates and outcomes for affected children.